Gemabank (MOEX: GEMA) is considering the possibility of placing additional ordinary shares via open subscription.
The volume of the additional issue may amount to up to 3.3 million shares. The price will be determined later based on the average market price of shares based on trading results for the preceding period.
The final decision on the placement and its terms will be made by the General Shareholders' Meeting on April 7, 2026.
Gemabank is a biotechnology company, part of the Artgen Biotech Group (MOEX: ABIO), developing drugs and services for prevention and therapy in oncohematology, immunology, and neurology.